Application of small molecule peptide FW in the preparation of drugs for alleviating Alzheimer's disease
By screening small-molecular peptide FW from royal jelly and combining commonly used pharmaceutical excipients, an Alzheimer's drug with antioxidant and acetylcholinesterase inhibitory effect was prepared, which solved the problem of major side effects of existing drugs and significantly alleviated the problem of significant relief. Cognitive dysfunction caused by oxidative stress.
Patent Information
- Application Number
- CN202311393470.4
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2023-10-26
- Publication Date
- 2024-12-06
- Estimated Expiration
- 2043-10-26
AI Technical Summary
The existing Alzheimer's treatment drugs have serious side effects and lack effective antioxidant and acetylcholinesterase inhibitors, making it difficult to effectively alleviate cognitive dysfunction caused by oxidative stress.
By screening and preparing small-molecular peptide FW from royal jelly, combined with pharmaceutical excipients such as water, glucose, magnesium stearate, etc., a drug that relieves Alzheimer's disease has antioxidant activity and acetylcholinesterase inhibitory effect. It can upregulate the early growth factor 1 (egr 1) gene and downregulate the expression of cysteine protease 3 (caspase 3) gene.
Small-molecule peptide FW significantly inhibits the key receptor proteins Fyn and Keap 1, which enhances the vitality of superoxide dismutase (SOD), has the potential to alleviate Alzheimer's disease and reduces the risk of drug side effects.
Smart Images

Figure CN117122667B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to application of small molecule peptide FW in preparing medicine for alleviating Alzheimer's disease, and belongs to the technical field of enzymatic processing products. Background Art
[0002] Royal jelly is a viscous pulp secreted by the hypopharyngeal gland and mandibular gland of honey bees. It has multiple active ingredients and multiple biological functions, such as lowering blood pressure and lipids, anti-oxidation and protecting the nervous system. However, royal jelly has low palatability and low processing utilization, which restricts its utilization value. Peptides have many advantages, such as being easy to digest and absorb, having low sensitivity, and easily passing through the blood-brain barrier. Therefore, enzymatic hydrolysis of royal jelly to obtain royal jelly hydrolysate and mining polypeptides with special biological activities from royal jelly hydrolysate are current research hotspots.
[0003] Alzheimer's disease (AD) is a common irreversible neurodegenerative disease in the elderly, with clinical manifestations such as progressive memory and cognitive impairment, language disorders, and psychomotor abnormalities. Oxidative stress, as a major factor in the progression of AD, promotes pathological formation by causing neuronal mitochondrial dysfunction, macromolecular oxidation, metal ion binding to Aβ plaques to produce reactive oxygen species (ROS), and upregulation of hyperphosphorylated tau protein and Aβ synthesis. Currently, drugs for the treatment of AD include cholinesterase inhibitors and n-methyl-d-aspartate receptor antagonists, which are accompanied by relatively serious side effects. Summary of the invention
[0004] In view of the above-mentioned prior art, the present invention provides the use of a small molecule peptide FW in the preparation of a drug for alleviating Alzheimer's disease, belonging to the technical field of enzymatic processing products.
[0005] The present invention is achieved through the following technical solutions:
[0006] Application of a small molecule peptide FW in the preparation of a drug for alleviating Alzheimer's disease, wherein the amino acid sequence of the small molecule peptide FW is Phe-Trp.
[0007] Furthermore, the active ingredient of the drug for alleviating Alzheimer's disease is the small molecule peptide FW.
[0008] Furthermore, the drug for alleviating Alzheimer's disease also contains excipients commonly used in pharmacy, and the excipients are selected from water, glucose, magnesium stearate, etc.; the dosage form of the drug for alleviating Alzheimer's disease is selected from common dosage forms, such as injection, oral solution, tablet, capsule, etc.
[0009] A drug for alleviating Alzheimer's disease, whose active ingredient is the small molecule peptide FW.
[0010] Furthermore, the drug for alleviating Alzheimer's disease also contains excipients commonly used in pharmacy, and the excipients are selected from water, glucose, magnesium stearate, etc.; the dosage form of the drug for alleviating Alzheimer's disease is selected from common dosage forms, such as injection, oral solution, tablet, capsule, etc.
[0011] Further, the drug for alleviating Alzheimer's disease is composed of the following components, by weight: small molecule peptide FW 0.2% to 1.0%, xylitol 6% to 10%, trehalose 1% to 3%, anhydrous citric acid 0.5% to 1.0%, β-cyclodextrin. 0.5% to 2.0%, potassium sorbate 0.03% to 0.08%, and the balance is water. Preferably, it is composed of the following components, by weight: small molecule peptide FW 0.5%, xylitol 8%, trehalose 2%, anhydrous citric acid 0.8%, β-cyclodextrin 1%, potassium sorbate 0.05%, and the balance is water.
[0012] The present invention has found through experimental research that royal jelly polypeptide has antioxidant activity, so royal jelly polypeptide has the potential to be used as a drug to alleviate Alzheimer's disease. Further, after LC-MS / MS identification, a small molecule peptide FW (present in royal jelly polypeptide R4) was screened from royal jelly polypeptide using molecular docking. The study found that the small molecule peptide FW has inhibitory activity on the key receptor proteins Fyn and Keap 1 that cause cognitive dysfunction caused by oxidative stress, has acetylcholinesterase (AchE) inhibitory effect, has an enhanced effect on the activity of superoxide dismutase (SOD), can upregulate the early growth response factor 1 (egr 1) gene and downregulate the expression of cysteine protease 3 (caspase 3) gene. Therefore, the small molecule peptide FW has the potential to be used as a drug to alleviate Alzheimer's disease.
[0013] Various terms and phrases used herein have the general meanings that are well known to those skilled in the art. BRIEF DESCRIPTION OF THE DRAWINGS
[0014] Figure 1 : Schematic diagram of the effect of protease on reducing power, in which the difference results are marked with letters, a, b, c, d, e represent the significance of the difference between different experimental groups, those with the same marked letter mean that the difference is not significant, and those with different marked letters mean that the difference is significant (p<0.05).
[0015] Figure 2 : Schematic diagram of the effect of enzyme addition amount on reducing power, in which the difference results are marked with letters, a, b, c, d represent the significance of the difference between different experimental groups, those with the same marked letter mean that the difference is not significant, and those with different marked letters mean that the difference is significant (p<0.05).
[0016] Figure 3: Schematic diagram of the effect of initial pH on reducing power, in which the difference results are marked with letters, a, b, c, d represent the significance of the difference between different experimental groups, those with the same marked letter mean that the difference is not significant, and those with different marked letters mean that the difference is significant (p<0.05).
[0017] Figure 4 : Schematic diagram of the effect of enzymatic hydrolysis temperature on reducing power, in which the difference results are marked with letters, a, b, c, d represent the significance of the difference between different experimental groups, those with the same marked letter are not significantly different, those with different marked letters are significantly different (p<0.05).
[0018] Figure 5 : Schematic diagram of the effect of the solid-liquid ratio on reducing power, in which the difference results are marked with letters, a, ab, b, c, d, e represent the significance of the difference between different experimental groups, those with the same marked letter mean that the difference is not significant, and those with different marked letters mean that the difference is significant (p<0.05).
[0019] Figure 6 : Schematic diagram of the effect of enzymatic hydrolysis time on reducing power, in which the difference results are marked with letters, a, b, c, d, e represent the significance of the difference between different experimental groups, those with the same marked letter are not significantly different, those with different marked letters are significantly different (p<0.05).
[0020] Figure 7 : Molecular weight distribution diagram of standard product and royal jelly hydrolysate.
[0021] Figure 8 : Schematic diagram of the separation results of the enzymatic hydrolysate by G-10 polysaccharide gel column chromatography.
[0022] Fig. 9 : Schematic diagram of the comparison of zebrafish acetylcholinesterase fluorescence values after sample treatment, where *p<0.05, **p<0.01 compared with the model control group.
[0023] Fig.10 : Schematic diagram of the comparison of superoxide dismutase activity in zebrafish after sample treatment, where, compared with the model control group, **p<0.01, ***p<0.001.
[0024] Fig.11 : Schematic diagram of the comparison of relative expression levels of egr 1 gene, among which, compared with the model control group, **p<0.01, ***p<0.001.
[0025] Fig.12: Schematic diagram of the comparison of relative expression levels of caspase 3 gene, among which, compared with the model control group, **p<0.01, ***p<0.001. DETAILED DESCRIPTION
[0026] The present invention will be further described below in conjunction with the embodiments. However, the scope of the present invention is not limited to the following embodiments. It will be appreciated by those skilled in the art that various changes and modifications may be made to the present invention without departing from the spirit and scope of the present invention.
[0027] The instruments, reagents, and materials involved in the following examples, unless otherwise specified, are all conventional instruments, reagents, and materials available in the prior art and can be obtained through regular commercial channels. The experimental methods, detection methods, etc. involved in the following examples, unless otherwise specified, are all conventional experimental methods and detection methods available in the prior art.
[0028] The royal jelly used in the following examples was purchased from Shandong Fengcai Health Industry Co., Ltd., placed in a sealed light-proof bag, and kept at -20°C for future use.
[0029] Example 1 Optimization of royal jelly enzymatic hydrolysis process
[0030] 1. Screening enzyme
[0031] (1) Accurately weigh 1g of royal jelly, add 10ml of distilled water to prepare a substrate solution with a solid-liquid ratio of 1:10, adjust the substrate solution to the optimal pH of acidic protease, neutral protease, papain, bromelain and alkaline protease (3.0-4.0, 6.0-7.0, 6.8-7.0, 6.0-8.0 and 8.0-11.0, respectively), add five kinds of protease at an enzyme dosage of 2000U / g (enzyme activity / royal jelly), and perform enzymolysis for 5 hours in a water bath shaker at 50℃ and 200rpm; boil the sample for 15 minutes to inactivate the enzyme, cool to room temperature, centrifuge at 8000rpm for 10 minutes, and measure the reducing power of the enzymatic supernatant. Three replicates were set for each group.
[0032] (2) Determination of in vitro reducing power: 0.5 ml of the sample was mixed with 0.5 ml of 0.2 M phosphate buffer (pH 6.6) and 0.5 ml of 1.0% (unit g / ml) potassium ferricyanide solution, and incubated in a 50°C water bath for 20 minutes. After cooling to room temperature, 0.5 ml of 10% (unit g / ml) trichloroacetic acid solution was added to stop the reaction. The mixture was centrifuged at 1500 g for 10 minutes, 1 ml of the supernatant was taken, and 1 ml of distilled water and 0.2 ml of 0.1% (unit g / ml) FeCl 3The solutions were mixed and reacted at room temperature in the dark for 10 minutes, and the absorbance was measured at 700 nm, with BHA (tert-butyl hydroxyanisole) as a positive control (concentration of 0.1 mg / ml).
[0033] The formula for calculating the in vitro reducing power is as follows:
[0034] In vitro reducing power (%) = (Abs 样品 / Abs 阳性对照 )×100%.
[0035] (3) Results: Schematic diagram of the effect of protease on reducing power Figure 1 As shown. Figure 1 It can be seen that the in vitro reducing ability of the enzymatic hydrolysis product of neutral protease is the strongest, reaching 107.82%, which is significantly better than the other four proteases. Therefore, neutral protease was selected for single factor optimization experiment, as detailed below.
[0036] 2. Optimization of enzyme dosage
[0037] Accurately weigh 1g of royal jelly, add 10ml of distilled water to prepare a substrate solution with a solid-liquid ratio of 1:10, adjust the initial pH of the substrate solution to 7.0, add neutral protease according to the enzyme amount of 1000, 2000, 3000, 4000, 5000U / g (enzyme activity / royal jelly), and enzymolyze for 5 hours in a water bath shaker at 50℃ and 200rpm. Boil the sample for 15 minutes to kill the enzyme, cool to room temperature, centrifuge at 8000rpm for 10 minutes, and measure the reducing power of the enzymatic supernatant. Set up three parallels for each group.
[0038] Results: The effect of enzyme addition on reducing power is shown in the figure Figure 2 As shown in the figure, with the increase of enzyme dosage, the reducing ability gradually increased. When the enzyme dosage was 4000U / g, the reducing ability decreased and then increased again. When the enzyme dosage was 3000U / g and 5000U / g, the reducing ability was significantly higher than that of other groups (P<0.05). For economic considerations, the neutral protease dosage of 3000U / g was selected for the next optimization.
[0039] 3. Optimization of initial pH
[0040] Accurately weigh 1g of royal jelly, add 10ml of distilled water to prepare a substrate solution with a solid-liquid ratio of 1:10, adjust the initial pH value of the substrate solution to 4, 5, 6, 7, and 8 with 1M hydrochloric acid and 1M NaOH solution, add neutral protease at an enzyme dosage of 3000U / g (enzyme activity / royal jelly), and enzymolyze for 5 hours at 50°C and 200rpm in a water bath shaker. Boil the sample for 15 minutes to kill the enzyme, cool to room temperature, centrifuge at 8000rpm for 10 minutes, and measure the reducing power of the enzymatic supernatant. Set up three parallels for each group.
[0041] Results: Schematic diagram of the effect of initial pH on reducing power Figure 3 As shown in Figure 2, with the increase of pH, the reducing ability of the enzymatic hydrolysate showed a trend of first increasing and then decreasing. When the initial pH was 6, the reducing ability reached 85.32%, which was significantly higher than that of other groups (P < 0.05). Therefore, the initial pH of 6 was selected for the next step of optimization.
[0042] 4. Optimization of enzymatic hydrolysis temperature
[0043] Accurately weigh 1g of royal jelly, add 10ml of distilled water to prepare a substrate solution with a solid-liquid ratio of 1:10, adjust the initial pH value of the substrate solution to 6, add neutral protease at an enzyme dosage of 3000U / g (enzyme activity / royal jelly), and perform enzymolysis for 5 hours at 30, 40, 50, 60, and 70°C and 200rpm. Boil the sample for 15 minutes to kill the enzyme, cool to room temperature, centrifuge at 8000rpm for 10 minutes, and measure the reducing power of the enzymatic supernatant. Set up three parallels for each group.
[0044] Results: Schematic diagram of the effect of enzymatic hydrolysis temperature on reducing power Figure 4 As shown in Figure 2, with the increase of temperature, the reducing ability of the enzymatic hydrolysis product showed a trend of first increasing and then decreasing. When the enzymatic hydrolysis temperature was 50°C, the reducing ability reached 97.72%, which was significantly higher than that of other groups (P<0.05). Therefore, the enzymatic hydrolysis temperature was selected as 50°C for the next optimization.
[0045] 5. Optimization of material-liquid ratio
[0046] Prepare substrate solutions with a solid-liquid ratio of 1:2, 1:4, 1:6, 1:8, 1:10, and 1:12, adjust the initial pH of the substrate solution to 6, add neutral protease at an enzyme dosage of 3000U / g (enzyme activity / royal jelly), and perform enzymolysis for 5 hours in a water bath shaker at 50°C and 200rpm. Boil the sample for 15 minutes to inactivate the enzyme, cool to room temperature, centrifuge at 8000rpm for 10 minutes, and measure the reducing power of the enzymatic supernatant. Set up three parallels for each group.
[0047] Results: Schematic diagram of the effect of material-liquid ratio on reducing power Figure 5 As shown in the figure, the reducing ability of the enzymatic hydrolysate weakened with the increase of the feed-liquid ratio. There was no significant difference between 1:2 and 1:4. The reducing ability reached 113.55% and 111.19%, but was significantly higher than other groups (P < 0.05). For economic considerations, the feed-liquid ratio of 1:4 was selected for the next optimization.
[0048] 6. Optimization of enzymatic hydrolysis time
[0049] Royal jelly was prepared into a substrate solution with a solid-liquid ratio of 1:4, the initial pH value of the substrate solution was adjusted to 6, and neutral protease was added at an enzyme dosage of 3000U / g (enzyme activity / royal jelly), and enzymolysis was performed for 2, 3, 4, 5, and 6 hours at 50°C and 200rpm in a water bath shaker. The sample was boiled for 15 minutes to inactivate the enzyme, cooled to room temperature, centrifuged at 8000rpm for 10 minutes, and the reducing power of the enzymatic supernatant was determined. Three parallels were set for each group.
[0050] Results: Schematic diagram of the effect of enzymatic hydrolysis time on reducing power Figure 6 As shown. With the extension of enzymatic hydrolysis time, the reducing capacity of the enzymatic hydrolysis product showed a trend of first strengthening and then weakening. When the enzymatic hydrolysis time was 3 hours and 4 hours, there was no significance, and the reducing capacity reached 141.93% and 143.92%, but the significance was significantly higher than that of other time groups (P < 0.05). Therefore, for economic considerations, the enzymatic hydrolysis time of 3 hours was selected for the next optimization.
[0051] 7. Orthogonal test optimization
[0052] According to the results of the single factor experiment, the levels of the four factors of solid-liquid ratio, initial pH value, temperature and enzyme addition were determined, and a 4-factor 3-level orthogonal experiment was set up to measure the reduction capacity and obtain the optimal enzymatic hydrolysis conditions (enzymatic hydrolysis time 3 hours). The orthogonal experimental design factor level table is shown in Table 1.
[0053] Table 1. Orthogonal experimental design factor level table
[0054]
[0055] The results of the orthogonal optimization experiment of royal jelly enzymatic hydrolysis are shown in Table 2. In Table 2, the difference in reducing power is marked by letters. a, b, c, d, f, g, and h represent the significance of the difference between different peptides. Those with the same letter are not significantly different, and those with different letters are significantly different (p<0.05). From the R value analysis, it can be seen that the primary and secondary effects of the liquid ratio, initial pH value, temperature and enzyme addition on the enzymatic hydrolysis effect are: B>A>C>D, that is, the liquid ratio has the greatest effect, and the temperature has the least effect on the enzymatic hydrolysis effect. The optimized combination is A3B1C3D1, that is, the liquid ratio is 1:3, the initial pH is 7, the enzymatic hydrolysis temperature is 45℃, and the enzyme addition amount is 4000U / g. The verified reducing power is 205.24%.
[0056] Table 2 Results of orthogonal optimization experiment on royal jelly enzymatic hydrolysis
[0057]
[0058] Example 2 Dextran gel filtration chromatography and activity analysis of each component
[0059] Royal jelly was prepared into a substrate solution with a solid-liquid ratio of 1:3, the initial pH value of the substrate solution was adjusted to 7, neutral protease was added at an enzyme amount of 4000U / g (enzyme activity / royal jelly), and enzymolysis was performed for 3 hours in a water bath shaker at 45°C and 200rpm to obtain royal jelly enzymolyzate.
[0060] The enzymatic hydrolysate fractions of <10 KDa and <5 KDa were obtained in sequence using a Vivaflow 50R (Sartorius, Germany) ultrafiltration membrane package, and the enzymatic hydrolysate fraction of <5 KDa was freeze-dried and stored at -20°C, referred to as R0, as the sample to be tested below. The ultrafiltration membrane package was washed with a 0.5 mol / l NaOH solution and sealed with a 10% ethanol solution and stored at 4°C.
[0061] The molecular weight distribution of the standard product and royal jelly hydrolysate was determined by high performance liquid chromatography. The molecular weight distribution of the standard product and royal jelly hydrolysate is shown in the figure below. Figure 7 As shown. The chromatographic conditions were set as follows: chromatographic column, TSK gel 2000SWXL300mm×7.8mm; mobile phase ratio of acetonitrile: water: trifluoroacetic acid = 45:55:0.1 (volume ratio); detection wavelength selected UV220nm; flow rate set to 0.5mL / min; column temperature set to 30℃, injection volume 10μl. Cytochrome C (12384Da), porcine insulin (5733.49Da), bacitracin (1422.69Da), and glutathione (307.32Da) were selected as the molecular weight standards for gel filtration columns.
[0062] Prepare the mobile phase with pure water and sonicate until there are no bubbles. Prepare the sample to be tested and the mixed standard with the mobile phase to 10 mg / ml and 8 mg / ml respectively, filter with a 0.22 μm microporous filter membrane and inject. Draw a standard curve according to the peak time of the standard, and calculate the molecular weight range of the polypeptide in the sample according to the drawn standard curve fitting. The molecular weight distribution results of polypeptides in royal jelly hydrolysate are shown in Table 3. The molecular weight is mainly concentrated below 485.47 Da, so Sephadex G-10 is selected as the filler of the chromatography column.
[0063] Table 3 Results of molecular weight distribution of polypeptides in royal jelly hydrolysate
[0064]
[0065] Add appropriate amount of ultrapure water to dextran gel G-10, let it stand and swell for 24 hours, remove the foam and impurities; repeatedly add ultrapure water, stir, let it stand and remove the upper impurities, repeat until there are no broken impurities in the upper layer. Add water in an appropriate proportion, and fill the filler into the 16mm×70cm chromatography column along the wall continuously to avoid stratification and bubbles. After the height of the chromatography column filler basically no longer changes, pump in ultrapure water to compact the filler until the height of the chromatography column no longer changes.
[0066] Loading: Prepare a sample solution of 100 mg / ml with a loading volume of 3 ml; the elution rate is 1.5 ml / min; the mobile phase is ultrapure water, collect the peak components and freeze-dry them, and determine the antioxidant activity of different components.
[0067] Results: The schematic diagram of the separation results of the enzymatic hydrolysate after G-10 dextran gel column chromatography is shown in Figure 8 As shown, the five elution peaks are named R1, R2, R3, R4, and R5. The eluates corresponding to R1 to R5 are collected in sequence and freeze-dried. The freeze-dried powder is compounded with water to form a solution with a concentration of 10 mg / ml, and the reducing power of each component is measured (expressed as a percentage of 0.1 mg / ml BHA). The reducing power measurement results of each component are shown in Table 4. Table 4 uses letter marking to mark the difference results of reducing power. A, b, c, d, e, and f represent the significance of the difference between different experimental groups. Those with the same letter are not significantly different, and those with different letters are significantly different (p<0.05). Elution peak R4 has the strongest reducing ability, so component R4 is selected for the next step of the experiment.
[0068] Table 4 Results of reducing power determination of each component
[0069]
[0070] Example 3 LC-MS / MS mass spectrometry identification of peptide composition of component R4
[0071] Peptide desalting: The lyophilized powder of component R4 in Example 2 was re-dissolved by adding an appropriate amount of 8M UA (uric acid), taking an appropriate amount of solution, adding an appropriate amount of (2-carboxyethyl)phosphine (TCEP) and chloroacetamide (CAA), incubating at 37°C for 1h, transferring the supernatant to a 10K ultrafiltration tube, centrifuging at 12000g for 15min, adding 200μl 8M UA, centrifuging at 12000g for 15min, then adding 200μl 0.2% TFA (trifluoroacetic acid), centrifuging at 12000g for 15min, repeating the process; collecting the filtrate, desalting with a C18 StageTip, and vacuum drying. After drying, the peptides were re-dissolved with 0.1% FA (formic acid), and the peptide concentration was determined by OD280 for LC-MS analysis.
[0072] LC-MS / MS analysis: An appropriate amount of peptides from each sample was chromatographed using a nanoliter flow rate Easy nLC 1200 chromatography system (Thermo Scientific, Thermo Fisher Scientific). Buffer: Liquid A is a 0.1% formic acid aqueous solution, and liquid B is a mixed solution of 0.1% formic acid, acetonitrile and water (of which acetonitrile is 80%). The chromatographic column was balanced with 100% liquid A. The sample was injected into the Trap Column (100μm*20mm, 5μm, C18, Dr. Maisch GmbH, Germany) and then passed through the chromatographic analysis column (75μm*150mm, 3μm, C18, Dr. Maisch GmbH) for gradient separation at a flow rate of 300nl / min.
[0073] The liquid phase separation gradient is as follows: 0min~2min, liquid B linear gradient is from 2% to 5%; 2min~44min, liquid B linear gradient is from 5% to 28%; 44min~51min, liquid B linear gradient is from 28% to 40%; 51min~53min, liquid B linear gradient is from 40% to 100%; 53min~60min, liquid B is maintained at 100%.
[0074] After peptide separation, DDA (data-dependent acquisition) mass spectrometry analysis was performed using a Q-Exactive Plus mass spectrometer (Thermo Scientific). The analysis time was 60 min, detection mode: positive ion, parent ion scan range: 50-750 m / z, primary mass spectrometry resolution: 60,000@m / z 200, AGC target: 3e6, primary Maximum IT: 50 ms.
[0075] The peptide secondary mass spectrometry analysis was collected according to the following method: after each full scan, the secondary mass spectra (MS2 scan) of the 20 highest intensity parent ions were triggered to collect, the secondary mass spectrometry resolution: 15,000@m / z 200, AGCtarget:1e5, secondary Maximum IT:50ms, MS2 Activation Type:HCD, Isolation window:1.6m / z, Normalized collisionenergy:28.
[0076] Database search: The mass spectrometry database search software used was MaxQuant 2.1.2.0, and the analysis parameter settings are shown in Table 5. The following protein databases were used: ncbi-Apis mellifera ligustica (Common honeybee) (Italian honeybee)
[7469] -1917-20230508.fasta and uniprot-Apis melliferaligustica (Common honeybee) (Italian honeybee)
[7469] -111-20230508.fasta.
[0077] Table 5 MaxQuant analysis parameter settings
[0078]
[0079] After mass spectrometry data retrieval, PSM FDR≤0.01 and Protein FDR≤0.01 were used as screening criteria for peptide, site and protein identification, respectively, and 195 peptides and 8 proteins were obtained for R4 component.
[0080] Example 4 Peptide screening, synthesis and verification
[0081] 1. Peptide activity prediction
[0082] First, we screened the peptides based on the probability of peptide mismatch (PEP), peptide match score (Score) and peptide peak intensity (Intensity), and eliminated those with zero score and intensity and too high mismatch rate. We used PeptideRanker to evaluate the possibility of peptides having biological activity and ranked them. Among the 195 peptides, 74 had scores greater than 0.5 and 21 had scores greater than 0.9.
[0083] The biological activities of 74 short peptides with a score greater than 0.5 in PeptideRanker (an online software for peptide scoring) were evaluated by searching the BIOPEP database, and the toxicity and PI values of the 74 short peptides were evaluated by toxicity evaluation using Toxin Pred (an online software for toxicity prediction). Most short peptides have the potential to lower blood pressure (ACE inhibition, renin inhibition, and release of vasoactive substances), lower blood sugar (DPP-IV inhibition, glucose absorption stimulation activity, and α-glucosidase inhibition activity), control pain (DPP-Ⅲ inhibition activity), and AChE inhibition activity, and a small number of them have antioxidant activity. A large number of statistical results of studies have found that the composition and site of amino acids play a crucial role in the antioxidant activity of peptides. The amino acid residues at the N-terminus of the active peptides that are aromatic amino acids or Pro may be the key sites for free radical scavenging. In addition, the end containing hydrophobic amino acids is more likely to enter the receptor active pocket and stably bind, and the hydrophobic amino acids at the N-terminus of the above-mentioned peptides account for 72%. Through evaluation, it was found that all 74 short peptides were non-toxic, and the pI value range was mostly between 5 and 7, and a few were between 9 and 11. 48 peptides were screened for molecular docking using the above conditions.
[0084] 2. Molecular docking
[0085] Ligand processing: Chemdraw 19.0 and Chem3D 19.0 software were used to draw the molecular structure of the peptide, optimized by MM2 force field, and saved as pdb files. AutoDock software (a software for molecular docking) was used to import and hydrogenate the pdb files and save them as pdbqt ligand files.
[0086] Receptor processing: The crystal structures of Fyn (2DQ7) and Keap 1 (6SP1) were downloaded from the PDB database, and the redundant chloride ions and water molecules were deleted using PyMOL software and saved as pdb files. The receptors 2DQ7 and 6SP1 were dehydrated and hydrogenated using AutoDock Tools software and saved as pdbqt receptor files for future use.
[0087] Molecular docking: Use the vina function of AutoDock Tools software to perform molecular docking and simulate the interaction between small peptide molecules and large protein molecules. Set the docking center coordinates of 2DQ7 to (-3.031, -9.266, 39.033) (x, y, z), the box size to 50×51×58, set the docking center coordinates of 6SP1 to (-26.315, 20.346, -16.173) (x, y, z), the box size to 51×51×49, and take the default values for other parameters. Then, dock the amino acids and peptide ligands with the 2DQ7 crystal structure one by one.
[0088] Results: The 48 peptides screened above were docked with 2DQ7 and 6SP1 by Vina simulation, and 14 small molecule peptides were screened for synthetic verification according to the Vina scores.
[0089] Example 5 Synthesis and Activity Verification of Small Molecule Peptides
[0090] 1. Synthesis
[0091] 14 small molecule peptides including PYPDW, WP, FW, etc. were synthesized by Sangon Biotech (Shanghai) Co., Ltd.
[0092] 2. Activity Verification
[0093] Determination of reducing power: Each small molecule peptide was prepared into a 10 mg / ml solution, and the in vitro reducing power of the small molecule peptide was determined according to the method in Example 1. The relevant properties and antioxidant activity verification results of the top 8 small molecule peptides in reducing power are shown in Table 6. In Table 6, the difference results of reducing power are marked with letters, and a, b, c, d, e, f, and g represent the significance of the difference between different small molecule peptides. Those with the same letter mark are not significantly different, and those with different letter marks are significantly different (p<0.05).
[0094] Table 6 Related properties and antioxidant activity verification results of the top 8 small molecule peptides in reducing power
[0095]
[0096] Note: (1) The reducing power is expressed as a percentage of 0.1 mg / ml BHA; (2) Due to the randomness of molecular docking results, the Vina score shown in the table is the average of the lowest values of the 9 docking results (Note: the lower the score, the better the docking result).
[0097] As shown in Table 6, among the 8 peptide segments, the small molecule peptide FW has a stronger reducing ability, and the small molecule peptide FW was selected for subsequent experiments.
[0098] Example 6 Detection of the efficacy of royal jelly enzymatic hydrolysate and peptide fragments in preventing and treating Alzheimer's disease
[0099] 1. Experimental Animals
[0100] Wild-type AB strain zebrafish were bred in natural pairs. Zebrafish aged 4 days post fertilization (4 dpf) were used for the determination of the maximum detectable concentration (MTC) for the prevention and treatment of Alzheimer's disease and the evaluation of acetylcholinesterase inhibition, superoxide dismutase effects, and related genes. Zebrafish were raised in 28°C fish water (water quality: 200 mg instant sea salt was added to 1 L of reverse osmosis water, conductivity was 450-550 μS / cm; pH was 6.5-8.5; hardness was 50-100 mg / L CaCO 3 ).
[0101] 2. MTC Assay
[0102] 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. The samples were given in water, and the concentrations of the samples are shown in Table 7. A normal control group and a model control group were set up at the same time, and the volume of each well was 3mL. Except for the normal control group, the other experimental groups were given aluminum chloride hexahydrate in water to establish a zebrafish dementia model. After treatment at 28℃ for 48h, the MTC of the samples on the model zebrafish was measured.
[0103] Results: See Table 7 for details. Under the experimental conditions, the zebrafish MTC of the small molecule peptide FW for the prevention and treatment of Alzheimer's disease was 62.5 μg / mL, so the concentration of 62.5 μg / mL was selected for subsequent experiments.
[0104] Table 7 Results of the maximum detection concentration test for the efficacy of samples in preventing and treating Alzheimer's disease (n=30)
[0105]
[0106] 3. Evaluation of acetylcholinesterase inhibition efficacy
[0107] 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. The samples were given water-soluble, and the positive control was donepezil hydrochloride (concentration 3.33μg / mL). At the same time, a normal control group and a model control group were set up, and the volume of each well was 3mL. Except for the normal control group, the other experimental groups were given aluminum chloride hexahydrate in water to establish a zebrafish dementia model. After 48h of treatment at 28℃, the acetylcholinesterase assay kit was used, and the data were collected using a multifunctional microplate reader to analyze the fluorescence value of acetylcholinesterase in zebrafish. The statistical analysis results of this indicator were used to evaluate the inhibitory efficacy of the sample on acetylcholinesterase. The statistical analysis results were expressed as mean±SE. SPSS27.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant.
[0108] Results: Under the experimental conditions, the small molecule peptide FW has a certain effect on the inhibition of acetylcholinesterase. The schematic diagram of the comparison of the fluorescence values of zebrafish acetylcholinesterase after sample treatment is shown in the figure. Fig. 9 shown.
[0109] 4. Effects on superoxide dismutase
[0110] 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. The samples were given water-soluble, and the positive control was donepezil hydrochloride (concentration 3.33μg / mL). At the same time, a normal control group and a model control group were set up, with a volume of 3mL per well, and three biological replicates were set up in parallel. Except for the normal control group, the other experimental groups were given aluminum chloride hexahydrate in water to establish a zebrafish dementia model. After 48h of treatment at 28℃, the SOD kit (WST-1 method) was used to collect data using a multifunctional microplate reader to analyze the SOD activity in zebrafish. The statistical analysis results of this indicator were used to evaluate the effect of the sample on superoxide dismutase. The statistical analysis results were expressed as mean±SE. SPSS27.0 software was used for statistical analysis, and p<0.05 indicated that the difference was statistically significant.
[0111] Results: Under the experimental conditions, the small molecule peptide FW has a certain effect on enhancing the activity of SOD. The schematic diagram of the comparison of superoxide dismutase activity of zebrafish after sample treatment is as follows Fig.10 shown.
[0112] 5. Impact on related genes
[0113] 4dpf wild-type AB strain zebrafish were randomly selected in a 6-well plate, and 30 zebrafish were treated in each well. The samples were given water-soluble, and the positive control was donepezil hydrochloride (concentration 3.33μg / mL). At the same time, a normal control group and a model control group were set up, with a volume of 3mL per well, and three biological replicates were set up in parallel. Except for the normal control group, the other experimental groups were given aluminum chloride hexahydrate in water to establish the zebrafish dementia model. After treatment at 28℃ for 24h, the total RNA of zebrafish in each group was extracted using an automatic nucleic acid extractor, and the total RNA concentration was determined using a UV-visible spectrophotometer. 2.00μg of total RNA from zebrafish samples was taken, and 20.0μL cDNA was synthesized according to the instructions of the cDNA first-strand synthesis kit. The expression of β-actin, egr 1 gene and caspase 3 gene was detected by q-PCR. β-actin was used as an internal reference for gene expression, and the relative RNA expression of egr 1 gene and caspase 3 gene was calculated. The statistical results were expressed as mean ± SE. SPSS 27.0 software was used for statistical analysis, and p < 0.05 indicated that the difference was statistically significant.
[0114] Studies have shown that egr 1 plays an important role in learning and long-term memory. In neurodegenerative diseases, cognitive impairment is associated with a decrease in egr 1, and the expression level of egr 1 is significantly reduced in AD mice. Bioinformatics analysis showed that a decrease in the expression level of egr 1 was significantly associated with cognitive impairment in AD patients and is one of the biomarkers of AD; egr 1 binds to the bace 1 promoter and blocks the activation of APP signals, ultimately inhibiting Aβ deposition and improving cognitive function in AD. Therefore, AD cognitive dysfunction can be improved by upregulating egr1 gene expression. Caspase 3 is a marker of cell apoptosis and is closely related to AD. The activation of caspase 3 is generally considered to be one of the main signs of cell apoptosis in the hippocampus. AlCl 3 It induces apoptosis in the rat brain by activating caspase3, thereby inducing AD.
[0115] Results: Under the experimental conditions, small molecule peptide FW can up-regulate egr 1 and down-regulate caspase 3 gene expression. Fig.11 As shown in Figure 2, the schematic diagram of the comparison of the relative expression of caspase 3 gene is as follows Fig.12 shown.
[0116] Example 7 Drugs for Alleviating Alzheimer's Disease
[0117] A drug for alleviating Alzheimer's disease, comprising the following components, by weight: 0.5% small molecule peptide FW, 8% xylitol, 2% trehalose, 0.8% anhydrous citric acid, 1% β-cyclodextrin, 0.05% potassium sorbate, and the balance is water; the dosage form is an oral solution.
[0118] The above examples are provided to those skilled in the art to fully disclose and describe how to make and use the claimed embodiments, and are not intended to limit the scope of the disclosure herein. Modifications that are obvious to those skilled in the art will fall within the scope of the appended claims.
Claims
1. Use of small molecule peptide FW as an active ingredient alone in the preparation of a drug for alleviating Alzheimer's disease, characterized in that: The amino acid sequence of the small molecule peptide FW is Phe-Trp; The drug for alleviating Alzheimer's disease also contains excipients commonly used in pharmacy, and the excipients are selected from water, glucose, and magnesium stearate; The dosage form of the drug for alleviating Alzheimer's disease is selected from injection, oral solution, tablet and capsule.
2. A drug for alleviating Alzheimer's disease, characterized in that: The invention is composed of the following components, calculated by weight: 0.5% of small molecule peptide FW, 8% of xylitol, 2% of trehalose, 0.8% of anhydrous citric acid, 1% of beta-cyclodextrin, 0.05% of potassium sorbate, and the balance is water.
